[OncoTargets and Therapy] While multimodal treatment can be curative in select cases of r/r pediatric sarcoma, treatment refractoriness remains a tremendous hurdle for clinicians.
The FDA has expanded the approval of Mylotarg (gemtuzumab ozogamicin; Pfizer) to include treatment of patients aged 1 month and older with newly-diagnosed CD33-positive acute myeloid leukemia.
Inadequate pain management during needle procedures has been associated with increased anxiety and decreased treatment compliance in children with cancer.
The application is supported by data from 2 pivotal open-label, randomized phase 3 trials (SIOPEL 6 and ACCL0431), which compared the efficacy of sodium thiosulfate plus cisplatin to cisplatin alone for the prevention of cisplatin-induced hearing loss.
The authors of this article emphasized the importance of actively involving a diverse group of interdisciplinary team members in the psychosocial care of these patients.
Of all types of fertility treatment examined, the only one that significantly increased the risk of cancer in children was frozen embryo transfer.
Although prolonged periods of neutropenia are common following induction and intensification of chemotherapy, this study showed that pediatric patients with AML can be safely managed in the outpatient setting after resolution of neutropenia.
Central nervous system relapse rates in pediatric acute lymphoblastic leukemia can be reduced with additional early doses of intrathecal chemotherapy.
Exercise tolerance was found to be associated with verbal fluency, dominant motor speed, and math academics, among other neurocognitive metrics.
No difference in event-free survival (EFS) was observed in children and adolescents with newly diagnosed Hodgkin lymphoma (HL) according to race/ethnicity; however, postrelapse mortality was found to be higher in nonwhite groups. The findings from this pooled, secondary analysis of data from phase 3 clinical trials of dose-dense, response-adapted therapy were published in the Journal…
